Immunic (NASDAQ:IMUX) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Immunic (NASDAQ:IMUX) in a research report released on Thursday,Benzinga reports. They currently have a $17.00 target price on the stock.

Several other equities analysts have also recently issued reports on IMUX. HC Wainwright started coverage on Immunic in a report on Monday, November 25th. They issued a “buy” rating and a $10.00 price target on the stock. StockNews.com downgraded shares of Immunic from a “hold” rating to a “sell” rating in a research report on Monday, February 10th. One investment analyst has rated the stock with a sell rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $12.67.

Immunic Trading Up 12.4 %

Shares of IMUX opened at $1.18 on Thursday. The business’s fifty day moving average price is $1.02 and its two-hundred day moving average price is $1.26. Immunic has a 52 week low of $0.92 and a 52 week high of $2.11.

Hedge Funds Weigh In On Immunic

Several hedge funds have recently added to or reduced their stakes in IMUX. Focus Partners Wealth grew its position in shares of Immunic by 1.1% during the 4th quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock worth $2,168,000 after buying an additional 23,610 shares during the period. 683 Capital Management LLC grew its holdings in Immunic by 2.2% during the fourth quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock valued at $700,000 after purchasing an additional 15,349 shares during the period. Millennium Management LLC grew its holdings in Immunic by 480.6% during the fourth quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock valued at $580,000 after purchasing an additional 479,846 shares during the period. Renaissance Technologies LLC increased its stake in Immunic by 45.6% in the fourth quarter. Renaissance Technologies LLC now owns 566,623 shares of the company’s stock valued at $567,000 after purchasing an additional 177,542 shares in the last quarter. Finally, Bridgeway Capital Management LLC raised its holdings in Immunic by 11.5% in the fourth quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock worth $215,000 after purchasing an additional 22,200 shares during the period. Institutional investors and hedge funds own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.